Prostate Cancer Clinical Trials in Cleveland

Showing 161-180 of 329 trials

Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

NCT02163317

This pilot clinical trial studies magnetic resonance (MRI)-guided focal stereotactic radiosurgery (SRS) in treating patients with low- or intermediate-risk localized prostate cancer. Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue.

Adenocarcinoma of the ProstateRecurrent Prostate CancerStage I Prostate Cancer+2 more

Case Comprehensive Cancer Center12 participantsStarted Feb 2016

Cleveland, Ohio, United States

SUSPENDEDPhase 2< 1 mile

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

NCT05361915

This is a phase 2, multicenter, open-label study to evaluate the efficacy of abivertinib with abiraterone in patients with metastatic castration-resistant prostate cancer.

Prostate CancerProstate Cancer Metastatic

Sorrento Therapeutics, Inc.100 participantsStarted Sep 2025

La Jolla, California, United States • Cleveland, Ohio, United States

TERMINATEDPhase 3< 1 mile

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

NCT04844749

To demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent as measured by radiographic progression-free survival.

Metastatic Castration-resistant Prostate CancerAndrogen Resistant Prostatic Cancer

Veru Inc.105 participantsStarted Jun 2021

Anchorage, Alaska, United States • Tucson, Arizona, United States • Tucson, Arizona, United States +37 more locations

Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent

Prostate Cancer Trials in Other Cities

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442)

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

COMbination of Bipolar Androgen Therapy and Nivolumab

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Exploratory PK and Imaging Study of PSMA-Targeted Trillium Compounds and PTI-122 in Metastatic Prostate Cancer

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Telomere Associated Variables (TAVs) in Prostate Cancer

Other Conditions in Cleveland